Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 05 2022
24 05 2022
Historique:
received:
17
08
2021
accepted:
13
05
2022
entrez:
24
5
2022
pubmed:
25
5
2022
medline:
27
5
2022
Statut:
epublish
Résumé
Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients' initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m
Identifiants
pubmed: 35610322
doi: 10.1038/s41598-022-12669-5
pii: 10.1038/s41598-022-12669-5
pmc: PMC9130298
doi:
Substances chimiques
CCNE1 protein, human
0
Cyclin E
0
Oncogene Proteins
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
8701Subventions
Organisme : NCI NIH HHS
ID : P30CA016672
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
J Cancer Res Clin Oncol. 2008 Feb;134(2):193-201
pubmed: 17636327
Eur J Cancer. 2014 Jan;50(1):99-110
pubmed: 24176298
Oncotarget. 2015 Aug 28;6(25):20801-12
pubmed: 26204491
Sci Rep. 2020 Feb 20;10(1):3080
pubmed: 32080210
J Med Chem. 2019 May 9;62(9):4233-4251
pubmed: 30543440
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
Ann Oncol. 2015 Feb;26(2):438-9
pubmed: 25403579
Nat Med. 1998 Dec;4(12):1371-6
pubmed: 9846573
Gynecol Oncol. 2014 Jun;133(3):624-31
pubmed: 24607285
Clin Chim Acta. 2012 Apr 11;413(7-8):663-8
pubmed: 22244930
Diagnostics (Basel). 2020 May 05;10(5):
pubmed: 32380689
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Oncotarget. 2018 Sep 7;9(70):33258-33270
pubmed: 30279957
BMC Gastroenterol. 2014 Apr 17;14:78
pubmed: 24742107
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Ann Oncol. 2015 May;26(5):1012-1018
pubmed: 25669829
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Genes Dev. 2000 Jan 1;14(1):34-44
pubmed: 10640274
Br J Cancer. 2012 Nov 6;107(10):1722-8
pubmed: 23079576
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Res. 2014 Feb 15;74(4):1141-52
pubmed: 24366882
Int J Clin Exp Pathol. 2014 May 15;7(6):3202-12
pubmed: 25031741
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Int J Oncol. 2016 Feb;48(2):506-16
pubmed: 26647729
Br J Cancer. 2014 Nov 11;111(10):2014-23
pubmed: 25314059
Clin Cancer Res. 2013 Nov 1;19(21):5960-71
pubmed: 24004674
Clin Cancer Res. 2018 Aug 1;24(15):3539-3549
pubmed: 29691297
Adv Exp Med Biol. 2017;1042:335-369
pubmed: 29357066
Cancer. 2010 Jun 1;116(11):2621-34
pubmed: 20336784
Mol Cell Biol. 2012 Oct;32(20):4226-36
pubmed: 22907750
Mod Pathol. 2017 Feb;30(2):297-303
pubmed: 27767100
Oncotarget. 2017 May 16;8(20):33796-33806
pubmed: 28430579
Anticancer Res. 2015 Jun;35(6):3393-7
pubmed: 26026100
Mod Pathol. 2010 Jun;23(6):844-55
pubmed: 20228782
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9282-9287
pubmed: 30150405
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
BMC Cancer. 2019 Jan 21;19(1):96
pubmed: 30665374
Clin Cancer Res. 2012 May 15;18(10):2922-9
pubmed: 22452943
Lung Cancer. 2014 Nov;86(2):121-5
pubmed: 25257766